ABSTRACT
Background Late-onset unexplained epilepsy (LoUE), defined as epilepsy onset after age 55 without an obvious cause, is an important risk factor for dementia. Studies have shown that 10-25% of individuals with LoUE develop dementia within three to four years following their first seizure. However, the mechanisms underlying progression from LoUE to dementia remain poorly understood. The goals of the ELUCID study are to identify risk factors associated with development of cognitive decline and dementia in LoUE, and to develop tools to identify patients at high risk for these outcomes and thereby establish a foundation for dementia prevention strategies in this population.
Methods and analysis ELUCID is a multi-center prospective longitudinal observational study that will enroll 600 participants aged 55 or older with LoUE across seven U.S. medical centers. Participants undergo a baseline evaluation that includes a detailed clinical history, cognitive testing, brain MRI, overnight scalp EEG, and blood biomarkers. Participants will be followed at six-month intervals to record cognitive and neurological changes, with the primary outcomes of interest being development of mild cognitive impairment and/or dementia. This study aims to establish LoUE disease subtypes based on biomarkers, cognitive trajectories, and imaging features, and to develop a risk stratification tool for predicting risk for cognitive decline and dementia in patients presenting with LoUE.
Ethics and Dissemination ELUCID has obtained IRB approval (# 2023P001566, August 2023), with the MassGeneral Brigham IRB serving as the single IRB of record. All de-identified study data will be made publicly available on completion of the study.
Competing Interest Statement
Dr. Lam has served as a paid consultant for Neurona Therapeutics and Acadia Pharmaceuticals and has received research support from Sage Therapeutics and Neurona Therapeutics. Dr. Westover is a co-founder, scientific advisor, consultant to, and has personal equity interest in Beacon Biosignals. The remaining authors have no conflicts of interest to disclose.
Funding Statement
This study was funded by NIH / NINDS (R01 NS130119)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of MassGeneral Brigham gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
This is a protocol paper for a prospective study. There are no data produced in the present work.
